Q-omics provides the consensus-scored DEFB108F profile across patient tissues and cancer cell-line models. DEFB108F expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DEFB108F is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, DEFB108F RNA expression shows 13,650 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, THCA, and TGCT as cancer lineages where DEFB108F shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEFB108F — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEFB108F survival associations across molecular data types. DEFB108F RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEFB108F RNA expression–survival associations across cancer types. High DEFB108F expression shows unfavorable associations in KIRC, THYM, UCEC, LUAD, STAD and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for DEFB108F RNA expression.
This table summarizes DEFB108F tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for DEFB108F. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DEFB108F shows lower tumor expression in THCA. The THCA box plot shows higher DEFB108F RNA expression in normal versus tumor tissue (log2 FC = −0.080, t-test p = .034).
This table shows molecular features associated with DEFB108F in patient tissues and cancer cell lines. In patient samples, DEFB108F shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
